AU2020384041A1 - Azabenzimidazole compound and medicine - Google Patents
Azabenzimidazole compound and medicine Download PDFInfo
- Publication number
- AU2020384041A1 AU2020384041A1 AU2020384041A AU2020384041A AU2020384041A1 AU 2020384041 A1 AU2020384041 A1 AU 2020384041A1 AU 2020384041 A AU2020384041 A AU 2020384041A AU 2020384041 A AU2020384041 A AU 2020384041A AU 2020384041 A1 AU2020384041 A1 AU 2020384041A1
- Authority
- AU
- Australia
- Prior art keywords
- methyl
- pyridin
- trifluoromethyl
- amino
- methoxymethyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Ophthalmology & Optometry (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019205344 | 2019-11-13 | ||
| JP2019-205344 | 2019-11-13 | ||
| PCT/JP2020/042247 WO2021095801A1 (ja) | 2019-11-13 | 2020-11-12 | アザベンゾイミダゾール化合物及び医薬 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2020384041A1 true AU2020384041A1 (en) | 2022-06-09 |
Family
ID=75912665
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2020384041A Pending AU2020384041A1 (en) | 2019-11-13 | 2020-11-12 | Azabenzimidazole compound and medicine |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US12528813B2 (https=) |
| EP (1) | EP4059933A4 (https=) |
| JP (1) | JP7627661B2 (https=) |
| KR (1) | KR102951288B1 (https=) |
| CN (1) | CN114929697A (https=) |
| AU (1) | AU2020384041A1 (https=) |
| BR (1) | BR112022008571A2 (https=) |
| CA (1) | CA3161582A1 (https=) |
| MX (1) | MX2022005649A (https=) |
| TW (1) | TW202128689A (https=) |
| WO (1) | WO2021095801A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT3792260T (pt) | 2018-05-08 | 2024-10-02 | Nippon Shinyaku Co Ltd | Compostos de azabenzimidazol e produtos farmacêuticos |
| CA3161582A1 (en) * | 2019-11-13 | 2021-05-20 | Nippon Shinyaku Co., Ltd. | Azabenzimidazole compound and medicine |
| JP7205657B1 (ja) | 2021-08-10 | 2023-01-17 | 小野薬品工業株式会社 | Ｅｐ４アンタゴニストの製造方法 |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5571819A (en) | 1994-11-22 | 1996-11-05 | Sabb; Annmarie L. | Imidazopyridines as muscarinic agents |
| NO2005012I1 (no) | 1994-12-28 | 2005-06-06 | Debio Rech Pharma Sa | Triptorelin og farmasoytisk akseptable salter derav |
| US6541669B1 (en) | 1998-06-08 | 2003-04-01 | Theravance, Inc. | β2-adrenergic receptor agonists |
| UA73543C2 (uk) | 1999-12-07 | 2005-08-15 | Тераванс, Інк. | Похідні сечовини, фармацевтична композиція та застосування похідного при приготуванні лікарського засобу для лікування захворювання, яке опосередковується мускариновим рецептором |
| EP1718642A4 (en) | 2004-02-25 | 2010-11-24 | Glaxosmithkline Llc | NEW CHEMICAL COMPOUNDS |
| TW200538095A (en) | 2004-03-11 | 2005-12-01 | Theravance Inc | Biphenyl compounds useful as muscarinic receptor antagonists |
| JP2007528418A (ja) | 2004-03-11 | 2007-10-11 | セラヴァンス， インコーポレーテッド | ムスカリンレセプターアンタゴニストとしての有用なジフェニルメチル化合物 |
| EP1734820A4 (en) | 2004-04-16 | 2008-01-23 | Neurogen Corp | Imidazopyrrazine, imidazopyridine, and imidazo-pyrimidine as CRF1 receptor ligands |
| EP2275095A3 (en) | 2005-08-26 | 2011-08-17 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation |
| ES2274712B1 (es) | 2005-10-06 | 2008-03-01 | Laboratorios Almirall S.A. | Nuevos derivados imidazopiridina. |
| JP5054770B2 (ja) | 2006-07-11 | 2012-10-24 | デウン ファーマシューティカル カンパニー リミテッド | 新規のビアリールベンゾイミダゾール誘導体及びこれを含む医薬組成物 |
| US8008307B2 (en) | 2006-08-08 | 2011-08-30 | Millennium Pharmaceuticals, Inc. | Heteroaryl compounds useful as inhibitors of E1 activating enzymes |
| GB0706168D0 (en) | 2007-03-29 | 2007-05-09 | Glaxo Group Ltd | Compounds |
| WO2009092764A1 (en) | 2008-01-24 | 2009-07-30 | Ucb Pharma, S.A. | Compounds comprising a cyclobutoxy group |
| ES2522968T3 (es) | 2008-06-04 | 2014-11-19 | Synergy Pharmaceuticals Inc. | Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos |
| US8110578B2 (en) | 2008-10-27 | 2012-02-07 | Signal Pharmaceuticals, Llc | Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway |
| PL2416761T3 (pl) | 2009-05-11 | 2015-07-31 | Ratiopharm Gmbh | Desfezoterodyna w postaci soli kwasu winowego |
| WO2011018894A1 (en) | 2009-08-10 | 2011-02-17 | Raqualia Pharma Inc. | Pyrrolopyrimidine derivatives as potassium channel modulators |
| JP5667934B2 (ja) | 2010-06-28 | 2015-02-12 | 大日本住友製薬株式会社 | 新規２環性複素環化合物からなる医薬 |
| TWI541243B (zh) | 2010-09-10 | 2016-07-11 | 拜耳知識產權公司 | 經取代咪唑并嗒 |
| JP2013545776A (ja) | 2010-12-17 | 2013-12-26 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 過剰増殖性障害の治療におけるｍｐｓ−１およびｔｋｋ阻害剤として使用するための６置換イミダゾピラジン |
| CA2821819A1 (en) | 2010-12-17 | 2012-06-21 | Marcus Koppitz | 6-substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders |
| SG11201400102WA (en) | 2011-08-24 | 2014-03-28 | Millennium Pharm Inc | Inhibitors of nedd8-activating enzyme |
| JP2013237634A (ja) | 2012-05-14 | 2013-11-28 | Dainippon Sumitomo Pharma Co Ltd | 縮環イミダゾロン誘導体 |
| HK1213245A1 (zh) | 2012-12-05 | 2016-06-30 | 奇斯药制品公司 | 作为pde4抑制剂的苯乙基吡啶衍生物 |
| BR112015019276A2 (pt) | 2013-02-19 | 2017-07-18 | Pfizer | compostos de azabenzimidazol como inibidores de isoenzimas de pde4 para o tratamento de distúrbios do snc e outros distúrbios |
| GB201302927D0 (en) | 2013-02-20 | 2013-04-03 | Cancer Therapeutics Crc Pty Ltd | Compounds |
| TWI647227B (zh) | 2013-02-28 | 2019-01-11 | 日商安斯泰來製藥股份有限公司 | ２－醯胺噻唑衍生物或其鹽 |
| US9326976B2 (en) | 2014-06-05 | 2016-05-03 | Chiesi Farmaceutici S.P.A. | Carbamate derivatives |
| US9951060B2 (en) | 2014-06-06 | 2018-04-24 | Astellas Pharma Inc. | 2-acylaminothiazole derivative or salt thereof |
| CN106573928B (zh) | 2014-08-26 | 2020-04-14 | 安斯泰来制药株式会社 | 2-氨基噻唑衍生物或其盐 |
| US10253023B2 (en) | 2014-10-06 | 2019-04-09 | Merck Patent Gmbh | Heteroaryl compounds as BTK inhibitors and uses thereof |
| JP6680297B2 (ja) | 2015-04-28 | 2020-04-15 | アステラス製薬株式会社 | 経口投与用医薬組成物 |
| WO2018112840A1 (en) | 2016-12-22 | 2018-06-28 | Merck Sharp & Dohme Corp. | 6, 5-fused heteroaryl piperidine ether allosteric modulators of the m4 muscarinic acetylcholine receptor |
| US11136324B2 (en) | 2017-03-03 | 2021-10-05 | Jiangsu Hansoh Pharmaceutical Group Co., Ltd. | Substituted imidazoles as apoptosis signal regulating kinase 1 inhibitors |
| KR102735800B1 (ko) | 2017-12-21 | 2024-11-28 | 교린 세이야쿠 가부시키가이샤 | 야간빈뇨 치료제 |
| JPWO2019189766A1 (ja) | 2018-03-30 | 2021-04-08 | 持田製薬株式会社 | 新規ビアリールアミド誘導体 |
| PT3792260T (pt) | 2018-05-08 | 2024-10-02 | Nippon Shinyaku Co Ltd | Compostos de azabenzimidazol e produtos farmacêuticos |
| TW202012415A (zh) | 2018-05-08 | 2020-04-01 | 瑞典商阿斯特捷利康公司 | 化學化合物 |
| US11203591B2 (en) | 2018-10-31 | 2021-12-21 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds |
| CA3161582A1 (en) * | 2019-11-13 | 2021-05-20 | Nippon Shinyaku Co., Ltd. | Azabenzimidazole compound and medicine |
| BR112022008457A2 (pt) | 2019-11-13 | 2022-07-26 | Nippon Shinyaku Co Ltd | Agente terapêutico e agente profilático para distúrbios gastrointestinais funcionais e xerostomia |
-
2020
- 2020-11-12 CA CA3161582A patent/CA3161582A1/en active Pending
- 2020-11-12 US US17/775,418 patent/US12528813B2/en active Active
- 2020-11-12 BR BR112022008571A patent/BR112022008571A2/pt unknown
- 2020-11-12 CN CN202080092956.2A patent/CN114929697A/zh active Pending
- 2020-11-12 KR KR1020227019556A patent/KR102951288B1/ko active Active
- 2020-11-12 MX MX2022005649A patent/MX2022005649A/es unknown
- 2020-11-12 AU AU2020384041A patent/AU2020384041A1/en active Pending
- 2020-11-12 JP JP2021556143A patent/JP7627661B2/ja active Active
- 2020-11-12 EP EP20886259.9A patent/EP4059933A4/en active Pending
- 2020-11-12 WO PCT/JP2020/042247 patent/WO2021095801A1/ja not_active Ceased
- 2020-11-13 TW TW109139704A patent/TW202128689A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2022005649A (es) | 2022-06-22 |
| JP7627661B2 (ja) | 2025-02-06 |
| KR20220100627A (ko) | 2022-07-15 |
| CA3161582A1 (en) | 2021-05-20 |
| US20230002395A1 (en) | 2023-01-05 |
| EP4059933A4 (en) | 2023-11-15 |
| US12528813B2 (en) | 2026-01-20 |
| CN114929697A (zh) | 2022-08-19 |
| WO2021095801A1 (ja) | 2021-05-20 |
| KR102951288B1 (ko) | 2026-04-13 |
| JPWO2021095801A1 (https=) | 2021-05-20 |
| TW202128689A (zh) | 2021-08-01 |
| BR112022008571A2 (pt) | 2022-08-09 |
| EP4059933A1 (en) | 2022-09-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2024200566A1 (en) | Pyridazinones as PARP7 inhibitors | |
| AU2011242711B2 (en) | Indazole compounds useful as ketohexokinase inhibitors | |
| KR20240005838A (ko) | 포스포닐 유도체 및 이의 조성물과 약학적 응용 | |
| AU2019265134B2 (en) | Azabenzimidazole compounds and pharmaceutical | |
| WO2023186069A1 (zh) | 一类白介素-1受体相关激酶4的双功能嵌合体杂环化合物及其制备方法、药用组合物和用途 | |
| CA3085460A1 (en) | Aryl-bipyridine amine derivatives as phosphatidylinositol phosphate kinase inhibitors | |
| US12528813B2 (en) | Substituted imidazo[4,5-b]pyridines as M3 receptor PAMs | |
| CN114805303A (zh) | 一种具有降解egfr双功能分子及其组合物和药学上的应用 | |
| TW202421151A (zh) | Ｗｅｅ１抑制劑及用於治療癌症之方法 | |
| AU2020382209A1 (en) | Therapeutic agent and prophylactic agent for functional gastrointestinal disorders and xerostomia | |
| TW202302585A (zh) | 具有四氫吲哚－１－甲醯胺作為ｂｃｌ－２抑制劑之化合物 | |
| KR20260022390A (ko) | Smarca2의 선택적 분해제로서의 이작용성 아진 접합체 및 이의 치료적 용도 | |
| HK40075503A (en) | Azabenzimidazole compound and medicine | |
| HK40076325A (en) | Azabenzimidazole compound and medicine | |
| RU2804485C2 (ru) | Азабензимидазольные соединения и фармкомпозиция | |
| HK40046611B (en) | Azabenzimidazole compounds and pharmaceutical | |
| HK40046611A (en) | Azabenzimidazole compounds and pharmaceutical | |
| WO2025117886A1 (en) | Ulk complex modulators and uses thereof | |
| WO2022253341A1 (en) | 2, 8-diazaspiro [4.5] decane compounds | |
| KR20260005249A (ko) | 옥소 피리도 지방족 고리 또는 지방족 헤테로고리 구조를 포함하는 화합물 및 이의 의학적 용도 | |
| CA3246917A1 (en) | C-MYC MESSENGER RIBONUCLE ACID (MRNA) TRANSLATION MODULATORS AND THEIR USES IN CANCER TREATMENT | |
| HK40045733A (en) | Azabenzimidazole compounds and pharmaceutical |